Lyell Immunopharma Announces FDA Clearance of its IND for LYL797, a CAR T-Cell Therapy Incorporating Novel Reprogramming Technologies for Solid Tumors
16 déc. 2021 16h05 HE
|
Lyell Immunopharma, Inc
Expects to begin screening patients for the Phase 1 clinical trial by the end of the first quarter; initial data presentation expected in 2023ROR1-targeted CAR T-cell therapy designed to overcome...
Lyell Immunopharma Announces cGMP Qualification of LyFE™ Manufacturing Center in Advance of Initiating Clinical Programs
15 déc. 2021 16h05 HE
|
Lyell Immunopharma, Inc
Lyell’s cGMP-compliant manufacturing facility, is designed to produce cell products at scale for upcoming clinical trials across its CAR, TIL and TCR programsLyFE Manufacturing Center integrates...
Lyell Immunopharma Announces Return of Dr. Rick Klausner as Board Chair
02 déc. 2021 16h05 HE
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients...
Lyell Immunopharma Reports Third Quarter 2021 Financial Results and Business Highlights
12 nov. 2021 08h00 HE
|
Lyell Immunopharma, Inc
Cash and investments of $936.4 million as of September 30, 2021 supports advancing multi-modality cell therapy pipeline SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Lyell...
Lyell Immunopharma to Participate in Morgan Stanley Global Healthcare Conference
08 sept. 2021 16h05 HE
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients...
Lyell Immunopharma Reports Second Quarter 2021 Financial Results and Business Highlights
12 août 2021 16h05 HE
|
Lyell Immunopharma, Inc
Achieved operational readiness of state-of-the-art LyFE manufacturing facility to support multiple clinical trialsCash, cash equivalents and marketable securities of $974.8 million as of June 30, 2021...
Lyell Immunopharma Announces Pricing of Initial Public Offering
16 juin 2021 21h49 HE
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients...